<DOC>
	<DOCNO>NCT00098241</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability RAD001 ( Certican ) administer pediatric renal transplant recipient , provide additional safety data .</brief_summary>
	<brief_title>Safety &amp; Efficacy Certican Pediatric de Novo Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male female patient 16 year age . Patients receive primary cadaveric nonHLA identical living donor ( relate unrelated ) renal transplant . The graft must functional within 48 hour post transplantation . Cold ischemia time great 40 hour . Patients recipients multiple solid organ transplant , include dual en bloc kidney , previously receive transplanted organ . Patients panel reactive T cell antibodies 50 % high last assessment transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pediatric</keyword>
	<keyword>renal</keyword>
	<keyword>transplant recipient</keyword>
	<keyword>de novo</keyword>
	<keyword>De novo renal pediatric transplant</keyword>
</DOC>